miRNA在新型冠状病毒肺炎中的研究进展  

Research progress of miRNA in COVID-19

作　　者：张若阳 舒强[1] ZHANG Ruoyang;SHU Qiang(Children's Hospital,Zhejiang University School of Medicine,Nation Clinical Research Center for Child Health,National Regional Medical Center for Children,Hangzhou 310052,China)

机构地区：[1]浙江大学医学院附属儿童医院,国家儿童健康与疾病临床医学研究中心,国家儿童区域医疗中心,浙江杭州310052

出　　处：《中国病原生物学杂志》2024年第10期1234-1238,共5页Journal of Pathogen Biology

基　　金：国家自然科学基金(No.82370080)。

摘　　要：新型冠状病毒肺炎是一种由新型冠状病毒引起的疾病,因其强大的传播能力,疫情波及了200多个国家和地区,已导致超过五百万人死亡。目前针对新型冠状病毒肺炎尚无特效疗法。已有研究发现机体微小核糖核酸(microRNA,miRNA)的水平在新型冠状病毒肺炎或疫苗接种后发生变化,这使基于miRNA进行诊疗成为可能。本文拟就miRNA在新型冠状病毒肺炎的诊断、治疗、预后判断和预防中的研究进展进行综述。Corona Virus Disease 2019(COVID-19)is a disease caused by SARS-CoV-2.Due to its strong dissemination ability,it has affected more than 2o0 countries and continents,resulting in over 5 million deaths.There is currently no specific therapy for the constantly mutating virus.It has been found that the level of microRNA(miRNA)alters after infection or vaccination,which makes miRNA based diagnosis and treatment possible.This article reviews the potential role of miRNA in the diagnosis,treatment,prognosis and prevention of COVID-19.

关 键 词：新型冠状病毒肺炎 新型冠状病毒 微小核糖核酸 诊断 治疗 预后判断 预防 综述 

分 类 号：R563.1[医药卫生—呼吸系统]